Cargando…
Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Since its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents...
Autores principales: | Moss, Marcia L., Minond, Dmitry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688260/ https://www.ncbi.nlm.nih.gov/pubmed/29230082 http://dx.doi.org/10.1155/2017/9673537 |
Ejemplares similares
-
In Silico and Experimental ADAM17 Kinetic Modeling as Basis for Future Screening System for Modulators
por: Bienstein, Marian, et al.
Publicado: (2022) -
ADAM17: An Emerging Therapeutic Target for Lung Cancer
por: Saad, Mohamed I., et al.
Publicado: (2019) -
ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma
por: Tripathi, Priya, et al.
Publicado: (2014) -
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
por: Schumacher, Neele, et al.
Publicado: (2019) -
ADAM10 and ADAM17 as Biomarkers Linked to Inflammation, Metabolic Disorders and Colorectal Cancer
por: Sikora-Skrabaka, Magdalena, et al.
Publicado: (2022)